Transforming lives through collaboration: a renewed commitment to global haemophilia care

Sobi and Sanofi commit to up to 5 years of support

A renew commitment to work with the WFH Humanitarian Aid Program was signed this week aiming to donate 100 million IUs of factor therapy per year that will be distributed by the WFH Humanitarian Aid Program worldwide to developing countries. Foundation S, and Sobi provided one billion IUs of treatment product, enabling the treatment of 22,219 people with inherited bleeding disorders (cumulative number).

Now, support will continue for up to 5 years of providing life-changing factor for both existing and new patients in more than 50 countries.

Changing lives and communities

The commitment to extend the collaboration was signed at the WFH 2025 Comprehensive Care Summit in Dubai, an important meeting for global haemophilia specialists to discuss new developments in the management and treatment of inherited bleeding disorders.

Co-signatory to the agreement, Lydia Abad-Franch, Head of R&D and Chief Medical Officer at Sobi, commented “Treating more people living with haemophilia helps both individuals and communities. Our donations mean that the excellent medical teams in haemophilia care centres in some of the most under-resourced communities can give their patients the care they need to live productive and happy lives. Importantly, the programme also offers training and knowledge sharing, which is an invaluable tool for medical professionals to learn from each other about diagnosis and treatment protocols.”

Making a difference with dedication and expertise

The renewed commitment is the result of hard work by a dedicated project team who have been committed to ensuring people with haemophilia receive continuous care – regardless of where they live in the world. Linnéa Stenius, Sobi’s Global Program Director for Haemophilia has been a critical part of the agreement process, she said:

“Being able to deliver Sobi’s life-changing medicines through this process is complex; across the entire transport, storage, and distribution chain, there are strict criteria that need to be followed. Working with the WFH Humanitarian Aid Program means our products can reach patients and countries which would not normally have access.” 

“For this process to be successful, it requires the expertise and dedication of the operational teams involved. We thank everyone who has been and continues to work with the program to deliver high-quality Sobi medicines to countries all over the world,” Linnéa added.

An ongoing lifeline for haemophilia patients

As the largest distributors donated treatment products, the World Federation of Haemophilia’s Humanitarian Aid Program has provided critical care to tens of thousands of people with haemophilia globally. Launched in 1996, the program has now treated nearly 30,000 patients across more than 112 countries. The true impact of the program is hard to estimate, but by introducing prophylaxis and enabling elective surgeries, the program has treated over 410,000 bleeds, facilitated more than 12,000 surgeries, and helped over 6,500 patients—mostly children—receive prophylactic treatment.

Committed to transforming Lives

The WFH Humanitarian Aid Program plays a crucial role in enabling haemophilia patients in under-resourced nations to return to education or work and improving health outcomes. For Sobi, participating in this initiative goes beyond donations—it embodies our commitment to transforming lives of those with rare and debilitating diseases. As Founding Visionary Partners, this renewed commitment demonstrates our recognition of the importance of this programme and our immense pride in our role in this global effort.

About the WFH Humanitarian Aid Program

The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring, and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our contributor. To learn more about the WFH Humanitarian Aid Program, www.treatmentforall.org.

Photo from World Federation of Hemophilia